Preoperative Short-Course Radiation Therapy in Rectal Cancer

Pham Nguyen Tuong\textsuperscript{1}, Pham Nguyen Cuong\textsuperscript{2}, Le Trong Hung\textsuperscript{1}, Nguyen Thanh Ai\textsuperscript{1} and Huynh Thanh Hai\textsuperscript{1}

1. Dept. of Radiation Oncology, Oncology Center, Hue Central Hospital, Hue city, 49000, Vietnam
2. Dept. of Histopathology, Hue Central Hospital, Hue city, 49000, Vietnam

Abstract: Purpose: To evaluate the benefits of preoperative short-course radiotherapy in locally advanced rectal cancer. Patients and methods: A prospective study of 30 rectal cancer patients at T3-4M0 stage and ECOG 0-2 performed preoperative short-course radiation therapy at Hue Central Hospital Vietnam between June 2016 and July 2018, using pelvic 3D-Conformal Radiation Therapy with the total radiation dose being 25 Gy in 5 fractions over five days. Results: Mean age 57.1 ± 13.6 with 46.7% of patients in the range of 41-60 year-old. Male/female ratio: 2/1. Tumour stage T3 and T4 was 70% and 30%, respectively; stage III and stage IV was 86.7% and 13.3%, respectively. Positive lymph node rates on endoscopic ultrasound were 85.7% in T3 and 77.8% in T4. Downstaging rate for stage III, T4 and T3 was 65.4%, 65.4% and 4.8%, respectively. For upper third of the rectum: 100% of T3 stage patients got no downstaging. For middle rectum: downstaging rate for stage III, T4 and T3 was 55.6%, 57.1% and 7.1%, respectively. For lower rectum: downstaging rate for stage III, T4 was 50.0% and 100.0%, respectively. No acute toxicity was seen, 86.7% of the patients performed laparoscopic sphincter-preserving surgery. Conclusion: For the treatment of locally advanced rectal cancer, neoadjuvant therapy is standard. Preoperative short-course radiation therapy is a reasonable therapeutic option because it demonstrates benefits in tumour downstaging especially for middle and lower rectum.

Key words: Rectal cancer, short-course radiation therapy, preoperative, downstaging, pelvic 3D-conformal radiation therapy.

1. Background

Colorectal cancer is one of the common cancers in the world, including Vietnam, the incidence rate is keeping increase. In developed countries, colorectal cancer ranks the second among all cancers in both sexes, which listed only after lung cancer in men and breast cancer in women. In Vietnam, colorectal cancer ranks the 6th in the most common 10 cancers with the ASR of 9.2/100,000 and the mortality rate of 5.0/100,000 people \cite{8, 10}. One-third of colorectal tumours arise in the rectum, more commonly in men. Most rectal cancer patients were at the advanced stage at time of diagnosed.

Radiation therapy plays an important role in rectal cancer management. Preoperative adjuvant radiotherapy is used in high-risk cases to improve resectability, reduce local recurrence, increase sphincter preservation, and improve overall survival and quality of life.

In Vietnam, there have been some studies of preoperative radiotherapy in locally advanced rectal cancer, applying long-course concurrent chemoradiation therapy. In this study, we applied preoperative short-course radiation therapy to evaluate the effectiveness in T3-4 stage rectal cancer management.

2. Patients and Method

A prospective study of 30 rectal cancer patients at T3-4M0 stage and ECOG 0-2 performed preoperative short-course radiation therapy at Hue Central Hospital Vietnam between June 2016 and July 2018, using pelvic 3D-conformal radiation therapy with the total radiation dose being 25 Gy in 5 fractions over five days.
Assessment of toxicity based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 of the National Cancer Institute (2009). Data were processed using SPSS 16.0 for Windows.

3. Results

3.1 Patients Characteristics

| Patients characteristics | No. | %  |
|--------------------------|-----|----|
| Age                      | 56.73 ± 14.34 (29-77) |
| Age group                |     |    |
| ≤ 40                     | 4   | 13.3 |
| 41-60                    | 14  | 46.7 |
| 60-80                    | 12  | 40.0 |
| Gender                   |     |    |
| Male                     | 20  | 66.7 |
| Female                   | 10  | 33.3 |
| Rectal tumour location   |     |    |
| Upper third              | 5   | 16.7 |
| Middle third             | 21  | 70.0 |
| Lower third              | 4   | 13.3 |
| Histopathology           |     |    |
| Adenocarcinoma           | 29  | 96.7 |
| Mucous adenocarcinoma    | 1   | 3.3 |
| Stage                    |     |    |
| T3                       | 21  | 70.0 |
| T4                       | 9   | 30.0 |
| Node                     |     |    |
| N0                       | 5   | 16.7 |
| N1                       | 13  | 43.3 |
| N2                       | 12  | 40.0 |
| Stage                    |     |    |
| II                       | 4   | 13.3 |
| III                      | 26  | 86.7 |

3.2 Treatment Outcomes

| Symptoms                  | Before radiotherapy | After radiotherapy |
|---------------------------|---------------------|--------------------|
|                           | No. | %  | n | %  |
| Rectal bleeding           | 26  | 86.7 | 6 | 20.0 |
| Mucus in stool            | 10  | 33.3 | 0 | 0   |
| Abdominal pain            | 15  | 50  | 8 | 26.7 |
| Constipation              | 13  | 43.3 | 5 | 17.2 |

| CEA level (ng/mL)         | Before radiotherapy | After radiotherapy |
|---------------------------|---------------------|--------------------|
|                           | No. | %  | n | %  |
| ≤ 5                       | 17  | 56.7 | 23 | 76.7 |
| > 5                       | 13  | 43.3 | 2  | 23.3 |

p = 0.006
Table 4  The change of disease stage.

| Stage | Before radiotherapy | No. | % |
|-------|---------------------|-----|---|
|       | II                  | 0   | 0 |
|       | III                 | 1   | 4 |
| Total |                     | 1   | 13.3 |

| Stage | After radiotherapy | Total |
|-------|--------------------|-------|
|       | I                  | II    | III  | IV   | No. | % |
| II    | 0                  | 2     | 1    | 1    | 4   | 13.3 |
| III   | 4                  | 13    | 8    | 0    | 26  | 86.7 |
|       |                     | 15    | 9    | 1    | 30  | 100.0 |

Downstaging rate for stage III was (26-9)/26 = 65.4%.

Table 5  The change of stage T and CEA level related to tumour location.

| Rectal tumour location | T stage and CEA (ng/mL) | Before radiotherapy | After radiotherapy |
|------------------------|-------------------------|---------------------|--------------------|
|                        | No. | % | No. | % |
| Upper third            |     |   |     |    |
| T3                     | 5   | 100 | 5   | 100 |
| T4                     | 0   | 0  | 0   | 0   |
| CEA ≤ 5                | 5   | 100 | 5   | 100 |
| CEA > 5                | 0   | 0  | 0   | 0   |
| Middle third           |     |   |     |    |
| T2                     | 0   | 0  | 0   | 23.8 |
| T3                     | 14  | 66.7 | 13  | 61.9 |
| T4                     | 7   | 33.3 | 3   | 14.3 |
| CEA ≤ 5                | 10  | 47.6 | 15  | 71.4 |
| CEA > 5                | 11  | 52.4 | 16  | 28.6 |
| Lower third            |     |   |     |    |
| T0                     | 0   | 0  | 1   | 25  |
| T2                     | 0   | 0  | 1   | 25  |
| T3                     | 2   | 50 | 2   | 50  |
| T4                     | 2   | 50 | 0   | 0   |
| CEA ≤ 5                | 2   | 50 | 3   | 75  |
| CEA > 5                | 2   | 50 | 1   | 25  |

With middle third: downstaging rate for stage T4 and T3 was (7-3)/7 = 57.1% and (14-13)/14 = 7.1%, respectively.

With lower third: downstaging rate for stage T4 was (2-0)/2 = 100.0%.

Table 6  The change of disease stage.

| Tumour location | Stage | After radiotherapy | Total |
|-----------------|-------|--------------------|-------|
|                 | II    | III    | IV    | No. | % |
| Higher rectum   |       |        |       |     |   |
| Before radiotherapy |     | I      | II    | III  | n  | % |
| II              | 0     | 0      | 1     | 1    | 1  | 20 |
| III             | 3     | 1      | 0     | 4    | 80 |
| Total           | 3     | 1      | 1     | 5    |   |
|                 |       |        |       |     |   |
| Middle rectum   |       |        |       |     |   |
| Before radiotherapy |     | II     | III   | IV   | n  | % |
| II              | 0     | 2      | 1     | 3    | 14.3 |
| III             | 3     | 8      | 7     | 18   | 85.7 |
| Total           | 3     | 10     | 8     | 21   |   |
|                 |       |        |       |     |   |
| Lower rectum    |       |        |       |     |   |
| Before radiotherapy |     | III    | II    | III  | n  | % |
| II              | 0     | 2      | 1     | 1    | 25.0 |
| III             | 1     | 1      | 2     | 4    | 100.0 |
| Total           | 1     | 1      | 2     | 4    |   |

For upper third of the rectum, after radiation, stage III remained only one case (four before) while the stage II case transferred to stage IV.

Downstaging rate for stage III for middle and lower third was (18-8)/18 = 55.6% and (4-2)/4 = 50.0%, respectively.
Table 7  Rate of laparoscopic surgery of sphincter preservation.

| Tumour location | sphincter-preserving surgery/number of patients |
|----------------|-----------------------------------------------|
| Upper rectum   | 4/5                                           |
| Middle rectum  | 19/21                                         |
| Lower rectum   | 3/4                                           |
| Total          | 26/30                                         |

(leck) Low anterior resection, Anterior resection, Pull-through.

4. Discussion

4.1 Patients Characteristics

In this study, the mean age was 56.73 ± 14.34 (29-77), 86.7% of the patients were above 40 years old in which 46.7% of the patients were in the range of 41-60 year-old. Male/female ratio was 2/1. The location of upper, middle and lower third of rectal cancer was 16.7%, 70.0% and 13.3%, respectively. Histopathology was adenocarcinoma, accounting for 96.7%, was similar to some Vietnamese studies such as Vo Van Xuan 83.9% [10], Vo Quoc Hung 87.4% [6], Pham Cam Phuong (89.6%) [8], Nguyen Van Hieu (89.8%) [5].

And 83.3% of the patients had positive lymph nodes on endoscopic ultrasound; 70% at T3 and 30% at T4 stage; and then 13.3% at stage II and 86.7% at stage III.

4.2 Treatment Results

Surgery is the mainstay of rectal cancer treatment. However, for locally advanced stages, the combination of treatment modalities including neooadjuvant therapy is neccessary in reducing the risk of cancer recurrence and shrinking the cancer prior to surgery.

4.2.1 Symptom Response

Table 2 showed that the majority of patients had significantly improved symptoms after radiotherapy. The symptom improvement demonstrated the role of short-course radiotherapy and was a greatly spiritual support for patients before surgery.

4.2.2 Biochemistry Response

Carcinoembryonic antigen (CEA), whose main application is mostly in gastrointestinal cancers, especially in colorectal malignancy, is one of the most widely used tumor markers worldwide. The clinical value of CEA in colorectal cancer is contributing to evaluating treatment outcomes and prognosis. In this study, we tried assessing the treatment response through the change of CEA concentration for each patient before and after treatment. The result showed that the highest reduction rate was 36.7%, the difference is statistically significant.

4.2.3 Stage Response

Response rate relating to disease stage III was 65.4%. For upper third of the rectum, at tumour stage T there was no change for 5 cases of T3. After radiation, there was only one case at stage III (four cases before radiation).

For middle third of the rectum, one remarkable thing was that 4 patients downstaged from T4 to T2, downstaging rate was 57.1%. The stage III before and after radiation accounted for 85.7% and 38.1%, respectively. After treatment, the proportion of patients with CEA ≥ 5 ng/mL decreased from 52.4% to 28.6%. These results demonstrated a significant improvement in downstaging and CEA concentration reduction in middle rectum.

For lower rectum, two T4 cases downstaged. After treatment, the proportion of patients with CEA ≥ 5 ng/mL decreased from 50% to 25%. Downstaging rate for stage III was 50%. According to Nguyen Van Hieu’s study, the T3 stage decreased from 67.7 to 61.3%, T4 stage decreased from 32.3% to 9.6%, the rate of T4 tumors decreased by 70% [5]; higher than the rate in Vo Quoc Hung’s study (51.8%) [6]. According to Pham Cam Phuong’s study, the overall downstaging rate was 46%, including 61.5% at stage IV and 39.3% at stage III [8].

The results of this study showed that lower and middle rectal tumours got response rate better than
ones in upper third of the rectum.

4.2.4 Toxicity and Sphincter-Preserving Surgery

In this study, 26 patients performed sphincter-preserving surgery including low anterior resection, anterior resection and Pull-through operation, accounting for 86.7%. According to Manisha Palta et al., a number of clinical trials showed that after short-course preoperative radiotherapy, the rate of sphincter-preserving surgery ranged from 61.2 to 63% [7]. Also according to Manisha Palta, the rate of grade 3-4 toxicity ranged from 1.9 to 3.2%, much lower than the rate in long-course concurrent chemoradiation therapy (18.2-28%). In this study, no acute toxicity was recorded. Because of the short follow-up duration, this study has not been able to assess local recurrence as well as progressive-free survival and overall survival.

5. Conclusion

Short-course preoperative adjuvant radiotherapy in stage T3-4 rectal cancers demonstrated benefits in improving symptoms, tumour downstaging and increasing sphincter preservation. Tumours in the middle and lower thirds of rectum got treatment response better than ones in upper rectum.

References

[1] Brooks, S. 2006. “Short Course Continuous, Hyperfractionated, Accelerated Radiation Therapy (CHART) as Preoperative Treatment for Rectal Cancer.” Acta Oncologica 45: 10791085.

[2] Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxi, A., and Cottone, M. 2000. “Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-Analysis.” JAMA 284 (8): 1008-15.

[3] Coucke, P. A., Notter, M., Stamm, B., Matter, M., Fasolini, F., Schlumpf, R., et al. 2006. “Preoperative Hyperfractionated Accelerated Radiotherapy (HART) in Locally Advanced Rectal Cancer (LARC) Immediately Followed by Surgery.” Radiotherapy and Oncology 79 (1): 52-8.

[4] Folkesson, J., Birgisson, H., Pahlman, L., Cedermark, B., and Glimelius, B. 2005. “Swedish Rectal Cancer Trial: Long Lasting Benefits From Radiotherapy on Survival and Local Recurrence rate.” Journal of Clinical Oncology 23 (24): 5644-50.

[5] Hieu, N. V., Quang, L. V., Toan, B. C., and Tuan, L. Q. 2017 “Evaluating the Results of Preoperative Radiotherapy for Invasive Rectal Cancer.” Vietnam Journal of Science and Technology, 1-4.

[6] Hung, V. Q. 2015. “Research on Clinical Characteristics, Histopathology of Rectal Cancer Group with Preoperative Radiotherapy at K Hospital.” Journal of Practical Medicine 876 (7): 79-81.

[7] Palta, M., Willett, C. G., and Czito, B. G. 2014. “Short-Course versus Long-Course Chemoradiation in Rectal Cancer-Time to Change Strategies?” Current Treatment Options in Oncology, June, doi: 10.1007/s11864-014-0296-2.

[8] Phuong, P. C., Khoa, M. T., and Hieu, N. V. 2012. “Evaluating the Effectiveness of Preoperative Radiotherapy in the Treatment of Invasive Rectal Cancer.” Vietnam Oncology Journal 4: 215-20.

[9] Glynne-Jones, R., Tan, D., Moran, B. J., and Goh, V. 2014. “How to Select for Preoperative Short-Course Radiotherapy, While Considering Long-Course Chemoradiotherapy or Immediate Surgery, and Who Benefits?” European Oncology & Haematology 10 (1): 17–24.

[10] Xuan, V. V., et al. 2012. “Research on the Application of Hyperaccelerated Preoperative Radiation for Rectal Cancer.” Vietnam Oncology Journal 2: 57-66.